Cancer antigen 125 level is determined by tricuspid regurgitation among patients with stable systolic heart failure
Öz
Abstract
Aim. Cancer antigen 125 (CA-125) is a soluble glycoprotein with high molecular weight. Recently, increased serum CA-125 levels were also documented in patients with heart failure (HF). We aimed to show what factors influence serum levels of CA-125 among patients with chronic systolic HF. Methods. Patients, who had chronic systolic HF with echocardiographically determined ejection fraction (EF) <45% were enrolled into final analysis (n=56). CA-125 levels were classified into two as those with normal (<35 U/mL) and high levels (≥35 U/mL). Results. Patients with Right ventricular (RV) dilatation had significantly higher CA-125 levels compared to those without RV dilatation. Besides, patients with RV dilatation had higher systolic pulmonary artery pressure (SPAP) levels compared to those without. Patients with high CA-125 levels had more frequent RV dilatation, higher pulmonary artery pressure, more severe tricuspid regurgitation. Tricuspid regurgitation was the only significant predictor of high CA-125 levels in patients with stable chronic systolic HF. Conclusion. It was shown in this study that tricuspid regurgitation was the only independent predictor of high CA-125 levels among patients with chronic stable systolic HF.
Keywords: CA-125, heart failure, right ventricle, tricuspid regurgitation
Özet
Amaç. Kanser antijen 125 (CA-125) yüksek molekül ağırlıklı çözülebilir bir glikoproteindir. Son yıllarda kalp yetersizliği (KY) hastalarında serum CA-125 düzeylerinin arttığı gösterilmiştir. Bu çalışmada kronik sistolik KY hastalarında serum CA-125 düzeylerini etkileyen faktörleri göstermeyi amaçladık. Yöntem. Sistolik KY ekokardiyografik olarak gösterilmiş, ejeksiyon fraksiyon <%45 olan hastalar son analize dahil edildi (n=56). CA-125 düzeyleri normal (<35 U/mL) ve yüksek (≥35 U/mL) olarak iki gruba ayrıldı. Bulgular. Sağ ventrikül (Sağ V) dilatasyonu olan hastalarda Sağ V dilatasyonu olmayanlara göre CA-125 düzeyleri anlamlı olarak daha yüksekti. Bunun yanında Sağ V dilatasyonu olan hastalarda olmayanlara göre sistolik pulmoner arter basıncı (SPAB) değerleri daha yüksekti. CA-125 düzeyleri yüksek olan hastalarda Sağ V dilatasyonu daha sık, SPAB daha yüksek, triküspit yetmezliği daha ciddiydi. Stabil kronik sistolik KY hastalarında sadece triküspit yetmezliği, yüksek CA-125 düzeyini predikte etmektedir. Sonuç. Bu çalışma göstermektedir ki stabil kronik kalp yetmezliği hastalarında, triküspit yetersizliği, yüksek CA-125 düzeylerinin bağımsız prediktörüdür.
Anahtar sözcükler: CA-125, kalp yetersizliği, sağ ventrikül, triküspit yetmezliğiAnahtar Kelimeler
CA-125 heart failure right ventricle tricuspid regurgitation
Kaynakça
- O’Brien TJ, Animator H, Knish I, Gee M. More than 15 years of CA125: What is known about the antigen, its structure and its function. Int J Biol Markers 1998; 13: 188-95.
- Barbieri RL, Niloff JM, Bast RC, Scaetzl E, Kistner RW, Knapp RC. Elevated serum concentrations of CA-125 in patients with advanced endometriosis. Fertil Steril 1986; 45: 630-4.
- Halila H, Stenman UH, Seppälä M. Ovarian cancer antigen CA 125 levels in pelvic inflammatory disease and pregnancy. Cancer 1986; 57: 1327-9. Zacharos ID, Efstathiou SP, Petreli E, Georgiou G, Tsioulos DI, Mastorantonakis SE. The prognostic signi.cance of CA 125 in patients with non-Hodgkin’s lymphoma. Eur J Haematol 2002; 69: 221-6.
- Nagele H, Bahlo M, Klapdor R, Schaeperkoetter D, Rodiger W. CA125 and its relation to cardiac function. Am Heart J 1999; 137: 1044-9.
- D’Aloia A, Faggiano P, Aurigemma G, Bontempi L, Ruggeri G, Metra M. Serum levels of carbohydrate antigen 125 in patients with chronic heart failure: Relation to clinical severity, hemodynamic and Doppler echocardiographic abnormalities, and short-term prognosis. J Am Coll Cardiol 2003 21; 41: 1805-11.
- Damy T, Viallet C, Lairez O, Deswarte G, Paulino A, Maison P. Comparison of four right ventricular systolic echocardiographic parameters to predict adverse outcomes in chronic heart failure. Eur J Heart Fail 2009; 11: 818-24.
- Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA. American Society of Echocardiography’s Nomenclature and Standards Committee; Task Force on Chamber Quantification; American College of Cardiology Echocardiography Committee; American Heart Association; European Association of Echocardiography, European Society of Cardiology. Recommendations for chamber quantification. Eur J Echocardiogr 2006; 7: 79
- Yock PG, Popp RL. Noninvasive estimation of right ventricular systolic pressure by Doppler ultrasound in patients with tricuspid regurgitation. Circulation 1984; 70: 657-62.
- Canney PA, Moore M, Wilkinson PM, James RD. Ovarian cancer antigen CA125: A prospective clinical assessment of its role as a tumor marker. Br J Cancer 1984; 50: 765-9.
- Duman D, Palit F, Simsek E, Bilgehan K. Serum carbohydrate antigen 125 levels in advanced heart failure: Relation to B-type natriuretic peptide and left atrial volume. Eur J Heart Fail 2008; 10: 556-9.
- Vizzardi E, Nodari S, D’Aloia A, Chiari E, Faggiano P, Metra M. CA 125 tumoral marker plasma levels relate to systolic and diastolic ventricular function and to the clinical status of patients with chronic heart failure. Echocardiography 2008; 25: 955-60.
- Turgut O, Tandogan I, Yilmaz MB, Gul I, Gurlek A. CA125 levels among patients with advanced heart failure: An emerging independent predictor for survival. Int J Cardiol 2009; 13.
- Kouris NT, Zacharos ID, Kontogianni DD, Goranitou GS, Sifaki MD, Grassos HE. The significance of CA125 levels in patients with chronic congestive heart failure. Correlation with clinical and echocardiographic parameters. Eur J Heart Fail 2005; 7: 199-203.
- Mathew B, Bhatia V, Mahy IR, Ahmed I, Francis L. Elevation of the tumor marker CA125 in right heart failure. South Med J 2004; 97: 1013-4.
- Lockhart CJ, McVeigh GE, Harbinson MT. Elevated CA 125 and ascites: Not always malignancy. Ir J Med Sci 2008; 177: 63-6.
- Yilmaz MB, Zorlu A, Tandogan I. Plasma CA-125 level is related to both sides of the heart: A retrospective analysis. Int J Cardiol 2009; 18.
Öz
Amaç. Kanser antijen 125 (CA-125) yüksek molekül ağırlıklı çözülebilir bir glikoproteindir. Son yıllarda kalp yetersizliği (KY) hastalarında serum CA-125 düzeylerinin arttığı gösterilmiştir. Bu çalışmada kronik sistolik KY hastalarında serum CA-125 düzeylerini etkileyen faktörleri göstermeyi amaçladık. Yöntem. Sistolik KY ekokardiyografik olarak gösterilmiş, ejeksiyon fraksiyon <%45 olan hastalar son analize dahil edildi (n=56). CA-125 düzeyleri normal (<35 U/mL) ve yüksek (≥35 U/mL) olarak iki gruba ayrıldı. Bulgular. Sağ ventrikül (Sağ V) dilatasyonu olan hastalarda Sağ V dilatasyonu olmayanlara göre CA-125 düzeyleri anlamlı olarak daha yüksekti. Bunun yanında Sağ V dilatasyonu olan hastalarda olmayanlara göre sistolik pulmoner arter basıncı (SPAB) değerleri daha yüksekti. CA-125 düzeyleri yüksek olan hastalarda Sağ V dilatasyonu daha sık, SPAB daha yüksek, triküspit yetmezliği daha ciddiydi. Stabil kronik sistolik KY hastalarında sadece triküspit yetmezliği, yüksek CA-125 düzeyini predikte etmektedir. Sonuç. Bu çalışma göstermektedir ki stabil kronik kalp yetmezliği hastalarında, triküspit yetersizliği, yüksek CA-125 düzeylerinin bağımsız prediktörüdür.
Anahtar Kelimeler
Kaynakça
- O’Brien TJ, Animator H, Knish I, Gee M. More than 15 years of CA125: What is known about the antigen, its structure and its function. Int J Biol Markers 1998; 13: 188-95.
- Barbieri RL, Niloff JM, Bast RC, Scaetzl E, Kistner RW, Knapp RC. Elevated serum concentrations of CA-125 in patients with advanced endometriosis. Fertil Steril 1986; 45: 630-4.
- Halila H, Stenman UH, Seppälä M. Ovarian cancer antigen CA 125 levels in pelvic inflammatory disease and pregnancy. Cancer 1986; 57: 1327-9. Zacharos ID, Efstathiou SP, Petreli E, Georgiou G, Tsioulos DI, Mastorantonakis SE. The prognostic signi.cance of CA 125 in patients with non-Hodgkin’s lymphoma. Eur J Haematol 2002; 69: 221-6.
- Nagele H, Bahlo M, Klapdor R, Schaeperkoetter D, Rodiger W. CA125 and its relation to cardiac function. Am Heart J 1999; 137: 1044-9.
- D’Aloia A, Faggiano P, Aurigemma G, Bontempi L, Ruggeri G, Metra M. Serum levels of carbohydrate antigen 125 in patients with chronic heart failure: Relation to clinical severity, hemodynamic and Doppler echocardiographic abnormalities, and short-term prognosis. J Am Coll Cardiol 2003 21; 41: 1805-11.
- Damy T, Viallet C, Lairez O, Deswarte G, Paulino A, Maison P. Comparison of four right ventricular systolic echocardiographic parameters to predict adverse outcomes in chronic heart failure. Eur J Heart Fail 2009; 11: 818-24.
- Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA. American Society of Echocardiography’s Nomenclature and Standards Committee; Task Force on Chamber Quantification; American College of Cardiology Echocardiography Committee; American Heart Association; European Association of Echocardiography, European Society of Cardiology. Recommendations for chamber quantification. Eur J Echocardiogr 2006; 7: 79
- Yock PG, Popp RL. Noninvasive estimation of right ventricular systolic pressure by Doppler ultrasound in patients with tricuspid regurgitation. Circulation 1984; 70: 657-62.
- Canney PA, Moore M, Wilkinson PM, James RD. Ovarian cancer antigen CA125: A prospective clinical assessment of its role as a tumor marker. Br J Cancer 1984; 50: 765-9.
- Duman D, Palit F, Simsek E, Bilgehan K. Serum carbohydrate antigen 125 levels in advanced heart failure: Relation to B-type natriuretic peptide and left atrial volume. Eur J Heart Fail 2008; 10: 556-9.
- Vizzardi E, Nodari S, D’Aloia A, Chiari E, Faggiano P, Metra M. CA 125 tumoral marker plasma levels relate to systolic and diastolic ventricular function and to the clinical status of patients with chronic heart failure. Echocardiography 2008; 25: 955-60.
- Turgut O, Tandogan I, Yilmaz MB, Gul I, Gurlek A. CA125 levels among patients with advanced heart failure: An emerging independent predictor for survival. Int J Cardiol 2009; 13.
- Kouris NT, Zacharos ID, Kontogianni DD, Goranitou GS, Sifaki MD, Grassos HE. The significance of CA125 levels in patients with chronic congestive heart failure. Correlation with clinical and echocardiographic parameters. Eur J Heart Fail 2005; 7: 199-203.
- Mathew B, Bhatia V, Mahy IR, Ahmed I, Francis L. Elevation of the tumor marker CA125 in right heart failure. South Med J 2004; 97: 1013-4.
- Lockhart CJ, McVeigh GE, Harbinson MT. Elevated CA 125 and ascites: Not always malignancy. Ir J Med Sci 2008; 177: 63-6.
- Yilmaz MB, Zorlu A, Tandogan I. Plasma CA-125 level is related to both sides of the heart: A retrospective analysis. Int J Cardiol 2009; 18.
Ayrıntılar
| Birincil Dil | İngilizce |
|---|---|
| Bölüm | Dahili Tıp Bilimleri Araştırma Yazıları |
| Yazarlar | |
| Yayımlanma Tarihi | 8 Nisan 2014 |
| Yayımlandığı Sayı | Yıl 2014Cilt: 36 Sayı: 2 |